source
- Incyte drops phase-1 JAK2 inhibitor to focus on next-generation candidatesIncyte announced it is abandoning its phase-1 JAK2V617F inhibitor, INCB160058, which was being tested in patients with myeloproliferative neoplasms. The decision was disclosed in the company's sec…
- Acrosian launches AI-focused biometrics CRO targeting pharma and biotechAcrosian has been introduced as a new contract research organization built for the AI era. The firm is founded by Benjamin Jackson, Soumitra Chowdhury and Vladimir Mats, who previously created the…